Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Levalbuterol in COPD
NCT00665600Phase 3Completed
- Sponsor
- Sumitomo Pharma America
- Start
- Feb 2002
- Primary completion
- Mar 2003
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial of levalbuterol in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Sumitomo Pharma America. Primary endpoint: Time-normalized area under the percent change from visit predose in FEV1 curve (nAUC0-8 hours) at Day 42. Started Feb 2002; status: completed.
02
Drugs
levalbuterol
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT00665600.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00665600.